After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
BMRN belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Biomarin Pharmaceutical Inc is $13.45B. A total of 1.22 million shares were traded on the day, compared to an average of 1.52M shares.
In the most recent transaction, Guyer Charles Greg sold 7,034 shares of BMRN for 71.28 per share on Mar 06 ’25. After the transaction, the EVP, Chief Technical Officer now owns 87,655 company shares. In a previous transaction on Mar 06 ’25, Guyer Charles Greg bought 7,034 shares at 71.28 per share.
Among the insiders who sold shares, Burkhart Erin disposed of 1,344 shares on Feb 24 ’25 at a per-share price of $68.38. This resulted in the GVP, Chief Accounting Officer holding 13,105 shares of BMRN after the transaction. In another insider transaction, Burkhart Erin bought 1,344 shares at $68.38 per share on Feb 24 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BMRN has a high of $94.85 and a low of $60.63.
As of this writing, BMRN has an earnings estimate of $0.97 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of $1.16 per share and a lower estimate of $0.71.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BMRN’s latest balance sheet shows that the firm has $1.01B in Cash & Short Term Investments as of fiscal 2021. There were $1.09B in debt and $546.50M in liabilities at the time. Its Book Value Per Share was $29.66, while its Total Shareholder’s Equity was $4.27B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMRN is Buy with a score of 4.56.
